A population-based analysis of changes in therapy of metastatic renal cell carcinoma (mRCC).

• DOI: 10.1200/jco.2014.32.15_suppl.e15586
• Publication Date: 2019-01-03T22:32:22Z
• Authors: Hannes Jurgens; Rena Tiigi; Kristiina Ojamaa; Helis Pokker; Kaire Innos; Peeter Padrik
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e15586 Background: The main therapy of mRCC before the era of targeted agents was immunotherapy with interferon-alfa (INFa) or interleukin-2. Current therapies include various sequencies of sunitin...